Evidence map›Paper›PMID 30511963›Full record

Trial reportThe Journal of clinical investigation2019

Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation.

Catia T Perciani, Bashir Farah, Rupert Kaul, Mario A Ostrowski, Salaheddin M Mahmud, Omu Anzala, Walter Jaoko, KAVI-ICR Team, Kelly S MacDonald

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02514018 (A Pilot Study to Characterize the Immune Response Induced by a Commercial Varicella Zoster Virus Vaccine in Healthy Adult Females in Nairobi, Kenya.), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02514018 phase4unknown statusnot on this map

A Pilot Study to Characterize the Immune Response Induced by a Commercial Varicella Zoster Virus Vaccine in Healthy Adult Females in Nairobi, Kenya.

TypeinterventionalSponsorUniversity of TorontoRan2015 to 2017Enrolled45ConditionsHealthyArmsLive-attenuated varicella-zoster virus vaccine
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Frontiers in immunology · 2022
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Catia T PercianiDepartment of Immunology, University of Toronto, Toronto, Ontario, Canada.
Bashir FarahKenyan AIDS Vaccine Initiative-Institute of Clinical Research (KAVI-ICR), University of Nairobi, Nairobi, Kenya.
Rupert KaulDepartment of Immunology, University of Toronto, Toronto, Ontario, Canada.
Mario A OstrowskiDepartment of Immunology, University of Toronto, Toronto, Ontario, Canada.
Salaheddin M MahmudCommunity Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Omu AnzalaKenyan AIDS Vaccine Initiative-Institute of Clinical Research (KAVI-ICR), University of Nairobi, Nairobi, Kenya.
Walter JaokoKenyan AIDS Vaccine Initiative-Institute of Clinical Research (KAVI-ICR), University of Nairobi, Nairobi, Kenya.
KAVI-ICR Team
Kelly S MacDonaldDepartment of Immunology, University of Toronto, Toronto, Ontario, Canada.
University of Nairobi · KEUniversity of Toronto · CASt. Michael's Hospital · CAUniversity Health Network · CAUniversity of Manitoba · CA

Funding

CIHR THA-11960
6 · The paper itself

Abstract

backgroundVaricella-zoster virus (VZV) is under consideration as a promising recombinant viral vector to deliver foreign antigens including HIV. However, new vectors have come under increased scrutiny, since trials with adenovirus serotype 5-vectored (Ad5-vectored) HIV vaccine demonstrated increased HIV risk in individuals with pre-immunity to the vector that was thought to be associated with mucosal immune activation (IA). Therefore, given the prospect of developing an HIV/VZV chimeric vaccine, it is particularly important to define the impact of VZV vaccination on IA.

methodsHealthy VZV-seropositive Kenyan women (n = 44) were immunized with high-dose live attenuated VZV vaccine, and we assessed the expression on CD4+ T cells isolated from blood, cervix, and rectum of IA markers including CD38 and HLA-DR and of markers of cell migration and tissue retention, as well as the concentration of genital and intestinal cytokines. A delayed-start group (n = 22) was used to control for natural variations in these parameters.

resultsAlthough immunogenic, VZV vaccination did not result in significant difference in the frequency of cervical activated (HLA-DR+CD38+) CD4+ T cells (median 1.61%, IQR 0.93%-2.76%) at 12 weeks after vaccination when compared with baseline (median 1.58%, IQR 0.75%-3.04%), the primary outcome for this study. VZV vaccination also had no measurable effect on any of the IA parameters at 4, 8, and 12 weeks after vaccination.

conclusionThis study provides the first evidence to our knowledge about the effects of VZV vaccination on human mucosal IA status and supports further evaluation of VZV as a potential vector for an HIV vaccine.

trial registrationClinicalTrials.gov NCT02514018.

fundingPrimary support from the Canadian Institutes for Health Research (CIHR). For other sources, see Acknowledgments.

Indexed as

AIDS VaccinesHerpesvirus 3, HumanVirus ActivationAdultCD4-Positive T-LymphocytesFemaleHIV-1HumansKenyaVaccines, AttenuatedVaricella Zoster Virus InfectionAIDS VaccinesVaccines, AttenuatedAIDS/HIVAIDS vaccineCytokinesT cellsVaccines

Identifiers

PMID30511963
PMCPMC6355215
OpenAlexW2902019463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.